KATRINA
KATRINA: Pembrolizumab (KeytrudA) in early Triple Negative breast cancer in Australia
Trial summary:
KATRINA is a multicentre, retrospective cohort study aiming to collect data related to patient and disease characteristics, treatment patterns and outcomes of early triple negative breast cancer in a routine clinical practice patient population, who have received pembrolizumab in the neoadjuvant setting via a medicine access program or reimbursed supply in Australia.
There is no direct involvement of patients in this study. The study is collecting data retrospectively from medical records. Patients will not be asked to complete any assessments for the study that is outside routine clinical practice. The total duration of the study is 5 years (June 2024 to June 2028), allowing for a median follow up period of 3.5 years.
Receptor status / problem studied:
Inclusion criteria
1) Patients of any age, gender and ECOG performance status with high risk, early stage TNBC who are enrolled in the pembrolizumab access program or accessed pembrolizumab via the PBS are eligible for enrolment to the study.
2) Patients must receive at least one dose of neoadjuvant pembrolizumab.
3) Note patients who have a non-active 2nd primary malignancy not currently receiving active treatment can be included.
Exclusion criteria
1) Patients who have not received any pembrolizumab or only received pembrolizumab in the adjuvant setting are not eligible for this study.
Trial Title
KATRINA
Diagnosis
Breast cancer
Type of trial
Collaborative
Type of treatement
Other
Phase
N/A